RT Journal Article
SR Electronic
T1 Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.11.21256908
DO 10.1101/2021.05.11.21256908
A1 Maria Cassia Mendes-Correa
A1 Lucy S. Villas-Boas
A1 Ana Luiza Bierrenbach
A1 Anderson de Paula
A1 Tania Regina Tozetto-Mendoza
A1 Fabio E. Leal
A1 Wilton Freire
A1 Heuder Gustavo Oliveira Paiao
A1 Andrea B C Ferraz
A1 Steven S. Witkin
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.11.21256908.abstract
AB Objectives To evaluate if antibodies induced by infection with a different SARS-CoV-2 virus strain neutralize the P.1 variant.Methods Convalescent sera from 60 individuals following a documented SARS-CoV-2 infection were assayed for neutralizing antibody titer against both strains.Results Fifty-six and 50 sera were positive for neutralizing antibodies against the ancestral and P.1 strains, respectively. Neutralization titers were higher against the ancestral strain, but in the majority of patients differences did not differ by more than a single dilution.Conclusions Neutralizing antibodies that were generated following infection with SARS-CoV-2 B.1.1.28 were effective in vitro, against the SARS-CoV-2 P.1. variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a research grant from MIM 52 do Hospital das Clinicas da Faculdade de Medicina da Universidade de SAo Paulo and by a research grant from Fundacao para Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), GRANT: (2020/05623-0).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee :Comissao Nacional de Etica em Pesquisa do Ministerio da Saude do Brasil (CONEP), protocol No. 30419320.7.0000.0068, dated April 18, 2020) and all subjects provided informed written consent. Ethical approval was given to the project.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at Instituto de Medicina Tropical de Sao Paulo, Brazil. The data that support the findings of this study are available on request from the corresponding author. http://www.imt.usp.br/